With most accountable care organizations (ACOs) continuing to participate in the upside-only track, the Medicare Shared Savings Program has not netted the savings that the Congressional Budget Office estimated in 2010. But some findings indicate the program will see greater savings as more ACOs transition to the downside-risk tracks and gain more years of experience.
With most accountable care organizations (ACOs) continuing to participate in the upside-only track of the Medicare Shared Savings Program (MSSP), a new analysis from Avalere has found that MSSP has not netted the savings that the Congressional Budget Office estimated in 2010.
According to the research, which was funded by the Pharmaceutical Research and Manufacturers of America, the fact that the MSSP has performed below CBO’s estimates raise questions about the long-term success of the alternative payment model. Avalere used 2012-2016 MSSP ACO participation and performance data to estimate aggregate net savings.
There are currently 562 ACO participants in MSSP, but most choose to participate in the track that does not require them to repay CMS if they spend above targets.
Avalere found that while CBO projected MSSP would produce $1.7 billion in net savings to the federal government from 2013 to 2016, the reality was that MSSP actually increased federal spending by $384 billion during that same time period.
However, previous research has shown that ACOs improve their performance as they gain years of experience, and Avalere’s analysis backs that up. ACOs in the fourth year of the program produced savings for the federal government totaling $152 million. According to Avalere, CBO may not have taken into account the time it would take for ACOs to gain experience before they produced consistent savings.
In addition to more experienced ACOs netting more savings, Avalere also found that ACOs in the tracks with downside risk also had greater savings and reduced federal spending by $60 million over 5 years compared with the upside-only ACOs that increased federal spending by $444 million. These findings suggest that CMS could potentially see greater savings as more ACOs transition to the downside-risk tracks.
“While data do suggest that more experienced ACOs and those accepting 2-sided risk may help the program to turn the corner in the future, the long-term sustainability of savings in the MSSP is unclear,” John Feore, director at Avalere Health, said in a statement. “ACOs continue to be measured against their past performance, which makes it harder for successful ACOs to continue to achieve savings over time.”
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
Value-Based Care Is Key to Bringing Cardiology Breakthroughs to Those Who Will Benefit Most
March 13th 2025On December 10, 2024, cardiologists, researchers, and value-based care experts gathered in Dallas, Texas, to discuss best practices for implementing advances in cardiology care with a value-based mindset, spanning the care continuum from prevention to treatment.
Read More